These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 27842995

  • 1. Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome.
    Feldman RA, O'Neill K, Butts SF, Dokras A.
    Fertil Steril; 2017 Jan; 107(1):276-281. PubMed ID: 27842995
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimüllerian hormone, free testosterone, and glucose disposal rate.
    Leonhardt H, Hellström M, Gull B, Lind AK, Nilsson L, Janson PO, Stener-Victorin E.
    Fertil Steril; 2014 Jun; 101(6):1747-56.e1-3. PubMed ID: 24661732
    [Abstract] [Full Text] [Related]

  • 4. ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome.
    Marchesan LB, Spritzer PM.
    Fertil Steril; 2019 Mar; 111(3):579-587.e1. PubMed ID: 30827526
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vigorous exercise is associated with superior metabolic profiles in polycystic ovary syndrome independent of total exercise expenditure.
    Greenwood EA, Noel MW, Kao CN, Shinkai K, Pasch LA, Cedars MI, Huddleston HG.
    Fertil Steril; 2016 Feb; 105(2):486-93. PubMed ID: 26551442
    [Abstract] [Full Text] [Related]

  • 7. High-molecular-weight adiponectin is inversely associated with sympathetic activity in polycystic ovary syndrome.
    Shorakae S, Abell SK, Hiam DS, Lambert EA, Eikelis N, Jona E, Sari CI, Stepto NK, Lambert GW, de Courten B, Teede HJ.
    Fertil Steril; 2018 Mar; 109(3):532-539. PubMed ID: 29428305
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum antimüllerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial.
    Nybacka Å, Carlström K, Fabri F, Hellström PM, Hirschberg AL.
    Fertil Steril; 2013 Oct; 100(4):1096-102. PubMed ID: 23876536
    [Abstract] [Full Text] [Related]

  • 10. A patient-specific model combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders.
    Vagios S, James KE, Sacha CR, Hsu JY, Dimitriadis I, Bormann CL, Souter I.
    Fertil Steril; 2021 Jan; 115(1):229-237. PubMed ID: 33077236
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C).
    Pankhurst MW, Shorakae S, Rodgers RJ, Teede HJ, Moran LJ.
    Fertil Steril; 2017 Nov; 108(5):851-857.e2. PubMed ID: 29079276
    [Abstract] [Full Text] [Related]

  • 12. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimüllerian hormone than its counterpart in a normal ovary: an observational cross-sectional study.
    Bhide P, Dilgil M, Gudi A, Shah A, Akwaa C, Homburg R.
    Fertil Steril; 2015 Feb; 103(2):537-41. PubMed ID: 25467043
    [Abstract] [Full Text] [Related]

  • 13. Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.
    Shandley LM, Fothergill A, Spencer JB, Mertens AC, Cottrell HN, Howards PP.
    Fertil Steril; 2018 Mar; 109(3):516-525.e1. PubMed ID: 29428311
    [Abstract] [Full Text] [Related]

  • 14. Associations of different molecular forms of antimüllerian hormone and biomarkers of polycystic ovary syndrome and normal women.
    Wissing ML, Mikkelsen AL, Kumar A, Kalra B, Pors SE, Flachs EM, Andersen CY.
    Fertil Steril; 2019 Jul; 112(1):149-155.e1. PubMed ID: 31056306
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients.
    Mes-Krowinkel MG, Louwers YV, Mulders AG, de Jong FH, Fauser BC, Laven JS.
    Fertil Steril; 2014 Jun; 101(6):1757-65.e1. PubMed ID: 24680368
    [Abstract] [Full Text] [Related]

  • 18. Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.
    Guedikian AA, Lee AY, Grogan TR, Abbott DH, Largaespada K, Chazenbalk GD, Dumesic DA.
    Fertil Steril; 2018 Mar; 109(3):508-515. PubMed ID: 29428312
    [Abstract] [Full Text] [Related]

  • 19. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
    Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe Andersen A.
    Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
    [Abstract] [Full Text] [Related]

  • 20. Elevated anti-Mullerian hormone in lean women may not indicate polycystic ovarian syndrome.
    Bradbury RA, Lee P, Smith HC.
    Aust N Z J Obstet Gynaecol; 2017 Oct; 57(5):552-557. PubMed ID: 28597496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.